Proto-Oncogene Proteins c-met
-
Subject Areas on Research
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.
- Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility.
- Activating mutation in MET oncogene in familial colorectal cancer.
- Acute tissue injury activates satellite cells and promotes sarcoma formation via the HGF/c-MET signaling pathway.
- An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
- Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas.
- Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
- Decreased fibronectin expression in Met/HGF-mediated tumorigenesis.
- Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway.
- Development of a Novel c-MET-Based CTC Detection Platform.
- Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.
- EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
- Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
- Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis.
- Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.
- Hepatocyte growth factor and myopia: genetic association analyses in a Caucasian population.
- Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5.
- Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases.
- Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma.
- Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
- MET and phosphorylated MET as potential biomarkers in lung cancer.
- Met and hepatocyte growth factor/scatter factor expression in human gliomas.
- Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.
- PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
- Pathogenic Germline Variants in 10,389 Adult Cancers.
- Personalized treatment of lung cancer.
- Profiling the dynamics of a human phosphorylome reveals new components in HGF/c-Met signaling.
- Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis.
- SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling.
- Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma.
- The role of cytoprotective cytokines in cardiac ischemia/reperfusion injury.
- Three-genome mosses: complex double allopolyploid origins for triploid gametophytes in Sphagnum.
- c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival.
-
Keywords of People
- Taylor, Gregory Alan, Associate Professor in Medicine, Immunology